Mycobacterium tuberculosis: immune response, biomarkers, and therapeutic intervention

Abstract

Although tuberculosis (TB) is an infectious disease, the progression of the disease following Mycobacterium tuberculosis (MTB) infection is closely associated with the host's immune response. In this review, a comprehensive analysis of TB prevention, diagnosis, and treatment was conducted from an immunological perspective. First, we delved into the host's immune response mechanisms against MTB infection as well as the immune evasion mechanisms of the bacteria. Addressing the challenges currently faced in TB diagnosis and treatment, we also emphasized the importance of protein, genetic, and immunological biomarkers, aiming to provide new insights for early and personalized diagnosis and treatment of TB. Building upon this foundation, we further discussed intervention strategies involving chemical and immunological treatments for the increasingly critical issue of drug-resistant TB and other forms of TB. Finally, we summarized TB prevention, diagnosis, and treatment challenges and put forward future perspectives. Overall, these findings provide valuable insights into the immunological aspects of TB and offer new directions toward achieving the WHO's goal of eradicating TB by 2035.

Keywords

biomarkers / diagnostic methods / immune checkpoints / immune response / mycobacterium tuberculosis (MTB) / therapeutic vaccines / tuberculosis (TB)

References

[1] Pai M, Behr MA, Dowdy D, et al. Tuberculosis. Nat Rev Dis Primers. 2016;2:16076.

[2] Barberis I, Bragazzi NL, Galluzzo L, Martini M. The history of tuberculosis: From the first historical records to the isolation of Koch's bacillus. J Prev Med Hyg. 2017;58(1):E9-E12.

[3] Gradmann C. Robert Koch and the pressures of scientific research: Tuberculosis and tuberculin. Med Hist. 2001;45(1):1-32.

[4] Bloom BR, Atun R, Cohen T, et al. Tuberculosis. In: Holmes KK, Bertozzi S, Bloom BR, Jha P, eds. Major Infectious Diseases. The International Bank for Reconstruction and Development/The World Bank; 2017.

[5] Bagcchi S. WHO's Global Tuberculosis Report 2022. Lancet Microbe. 2023;4(1):e20.

[6] Singh Dewhare S. Drug resistant tuberculosis: Current scenario and impending challenges. Indian J Tuberc. 2022;69(2):227-233.

[7] Esterhuyse MM, Linhart HG, Kaufmann SH. Can the battle against tuberculosis gain from epigenetic research? Trends Microbiol. 2012;20(5):220-226.

[8] Gong W, Pan C, Cheng P, Wang J, Zhao G, Wu X. Peptide-based vaccines for tuberculosis. Front Immunol. 2022;13:830497.

[9] Zhuang L, Ye Z, Li L, Yang L, Gong W. Next-generation TB vaccines: Progress, challenges, and prospects. Vaccines (Basel). 2023;11(8):1304.

[10] Hunter RL. Tuberculosis as a three-act play: A new paradigm for the pathogenesis of pulmonary tuberculosis. Tuberculosis (Edinb). 2016;97:8-17.

[11] Guirado E, Mbawuike U, Keiser TL, et al. Characterization of host and microbial determinants in individuals with latent tuberculosis infection using a human granuloma model. mBio. 2015;6(1):e02537.

[12] Gong W, Wu X. Differential diagnosis of latent tuberculosis infection and active tuberculosis: A key to a successful tuberculosis control strategy. Front Microbiol. 2021;12(3126):745592.

[13] Kahwati LC, Feltner C, Halpern M, et al. Primary care screening and treatment for latent tuberculosis infection in adults: Evidence report and systematic review for the US Preventive Services Task Force. Jama. 2016;316(9):970-983.

[14] Boom WH, Schaible UE, Achkar JM. The knowns and unknowns of latent Mycobacterium tuberculosis infection. J Clin Invest. 2021;131(3):e136222.

[15] Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124(4):783-801.

[16] Sia JK, Rengarajan J. Immunology of Mycobacterium tuberculosis infections. Microbiol Spectr. 2019;7(4).

[17] Malech HL, Deleo FR, Quinn MT. The role of neutrophils in the immune system: An overview. Methods Mol Biol. 2014;1124:3-10.

[18] Borkute RR, Woelke S, Pei G, Dorhoi A. Neutrophils in tuberculosis: Cell biology, cellular networking and multitasking in host defense. Int J Mol Sci. 2021;22(9):4801.

[19] Eum SY, Kong JH, Hong MS, et al. Neutrophils are the predominant infected phagocytic cells in the airways of patients with active pulmonary TB. Chest. 2010;137(1):122-128.

[20] Kobayashi SD, DeLeo FR. Role of neutrophils in innate immunity: A systems biology-level approach. Wiley Interdiscip Rev Syst Biol Med. 2009;1(3):309-333.

[21] Hayashi F, Means TK, Luster AD. Toll-like receptors stimulate human neutrophil function. Blood. 2003;102(7):2660-2669.

[22] Su R, Peng YP, Deng Z, et al. Mycobacterium tuberculosis infection induces low-density granulocyte generation by promoting neutrophil extracellular trap formation via ROS pathway. Front Microbiol. 2019;10:1468.

[23] Butov D, Kuzhko MM, Kalmykovа I, et al. Changes in nitric oxide synthase and nitrite and nitrate serum levels in patients with or without MDR-TB undergoing the intensive phase of anti-tuberculosis therapy. Int J Mycobacteriol. 2014;3(2):139-143.

[24] Sarr D, Tóth E, Gingerich A, Rada B. Antimicrobial actions of dual oxidases and lactoperoxidase. J Microbiol. 2018;56(6):373-386.

[25] Jamaati H, Mortaz E, Pajouhi Z, et al. Nitric oxide in the pathogenesis and treatment of tuberculosis. Front Microbiol. 2017;8:2008.

[26] Adams LB, Dinauer MC, Morgenstern DE, Krahenbuhl JL. Comparison of the roles of reactive oxygen and nitrogen intermediates in the host response to Mycobacterium tuberculosis using transgenic mice. Tuber Lung Dis. 1997;78(5-6):237-246.

[27] Jones GS, Amirault HJ, Andersen BR. Killing of Mycobacterium tuberculosis by neutrophils: A nonoxidative process. J Infect Dis. 1990;162(3):700-704.

[28] Alcantara CA, Glassman I, Nguyen KH, Parthasarathy A, Venketaraman V. Neutrophils in Mycobacterium tuberculosis. Vaccines (Basel). 2023;11(3):631.

[29] Warren E, Teskey G, Venketaraman V. Effector mechanisms of neutrophils within the innate immune system in response to Mycobacterium tuberculosis infection. J Clin Med. 2017;6(2):15.

[30] Barrios-Payán J, Aguilar-León D, Lascurain-Ledezma R, Hernández-Pando R. [Neutrophil participation in early control and immune activation during experimental pulmonary tuberculosis]. Gac Med Mex. 2006;142(4):273-281.

[31] Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol. 2005;5(12):953-964.

[32] Pollard JW. Trophic macrophages in development and disease. Nat Rev Immunol. 2009;9(4):259-270.

[33] Bogdan C. Macrophages. Encyclopedia of Life Sciences. John Wiley & Sons, Ltd; 2006.

[34] Weiss G, Schaible UE. Macrophage defense mechanisms against intracellular bacteria. Immunol Rev. 2015;264(1):182-203.

[35] Shukla S, Richardson ET, Drage MG, Boom WH, Harding CV. Mycobacterium tuberculosis Lipoprotein and lipoglycan binding to Toll-like receptor 2 correlates with agonist activity and functional outcomes. Infect Immun. 2018;86(10):e00450.

[36] Drage MG, Pecora ND, Hise AG, et al. TLR2 and its co-receptors determine responses of macrophages and dendritic cells to lipoproteins of Mycobacterium tuberculosis. Cell Immunol. 2009;258(1):29-37.

[37] Windheim M, Lang C, Peggie M, Plater LA, Cohen P. Molecular mechanisms involved in the regulation of cytokine production by muramyl dipeptide. Biochem J. 2007;404(2):179-190.

[38] Chen X, Xiao Z, Xie X, et al. TNF-α-induced NOD2 and RIP2 contribute to the up-regulation of cytokines induced by MDP in monocytic THP-1 cells. J Cell Biochem. 2018;119(7):5072-5081.

[39] Ochoa AE, Congel JH, Corley JM, et al. Dectin-1-independent macrophage phagocytosis of Mycobacterium abscessus. Int J Mol Sci. 2023;24(13):11062.

[40] Vergne I, Chua J, Singh SB, Deretic V. Cell biology of mycobacterium tuberculosis phagosome. Annu Rev Cell Dev Biol. 2004;20:367-394.

[41] Gordon AH, Hart PD. Stimulation or inhibition of the respiratory burst in cultured macrophages in a mycobacterium model: Initial stimulation is followed by inhibition after phagocytosis. Infect Immun. 1994;62(10):4650-4651.

[42] Trivedi A, Singh N, Bhat SA, Gupta P, Kumar A. Redox biology of tuberculosis pathogenesis. Adv Microb Physiol. 2012;60(60):263-324.

[43] Lu Y, Chen H, Wang P, et al. Identification and quantification of S-sulfenylation proteome of Mycobacterium tuberculosis under oxidative stress. Microbiol Spectr. 2023;11(2):e0338622.

[44] Shapouri-Moghaddam A, Mohammadian S, Vazini H, et al. Macrophage plasticity, polarization, and function in health and disease. J Cell Physiol. 2018;233(9):6425-6440.

[45] Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008;8(12):958-969.

[46] Marino S, Cilfone NA, Mattila JT, Linderman JJ, Flynn JL, Kirschner DE. Macrophage polarization drives granuloma outcome during Mycobacterium tuberculosis infection. Infect Immun. 2015;83(1):324-338.

[47] Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol. 2001;22(11):633-640.

[48] Caligiuri MA. Human natural killer cells. Blood. 2008;112(3):461-469.

[49] Lanier LL, Testi R, Bindl J, Phillips JH. Identity of Leu-19 (CD56) leukocyte differentiation antigen and neural cell adhesion molecule. J Exp Med. 1989;169(6):2233-2238.

[50] Bald T, Krummel MF, Smyth MJ, Barry KC. The NK cell-cancer cycle: Advances and new challenges in NK cell-based immunotherapies. Nat Immunol. 2020;21(8):835-847.

[51] Abebe F. Immunological basis of early clearance of Mycobacterium tuberculosis infection: The role of natural killer cells. Clin Exp Immunol. 2021;204(1):32-40.

[52] Esin S, Counoupas C, Aulicino A, et al. Interaction of Mycobacterium tuberculosis cell wall components with the human natural killer cell receptors NKp44 and Toll-like receptor 2. Scand J Immunol. 2013;77(6):460-469.

[53] Liu CH, Liu H, Ge B. Innate immunity in tuberculosis: Host defense vs pathogen evasion. Cell Mol Immunol. 2017;14(12):963-975.

[54] Collin M, Bigley V. Human dendritic cell subsets: An update. Immunology. 2018;154(1):3-20.

[55] Xin HM, Peng YZ, Yuan ZQ, Guo H. In vitro maturation and migration of immature dendritic cells after chemokine receptor 7 transfection. Can J Microbiol. 2009;55(7):859-866.

[56] Ehlers S. DC-SIGN and mannosylated surface structures of Mycobacterium tuberculosis: A deceptive liaison. Eur J Cell Biol. 2010;89(1):95-101.

[57] Liu J, Zhang X, Chen K, et al. CCR7 chemokine receptor-inducible lnc-Dpf3 restrains dendritic cell migration by inhibiting HIF-1α-mediated glycolysis. Immunity. 2019;50(3):600-615.e15.

[58] Fucikova J, Palova-Jelinkova L, Bartunkova J, Spisek R. Induction of tolerance and immunity by dendritic cells: Mechanisms and clinical applications. Front Immunol. 2019;10:2393.

[59] Ye Z, Chen Z, Sami A, El-Gayed A, Xiang J. Human dendritic cells engineered to express alpha tumor necrosis factor maintain cellular maturation and T-cell stimulation capacity. Cancer Biother Radiopharm. 2006;21(6):613-622.

[60] Jasenosky LD, Scriba TJ, Hanekom WA, Goldfeld AE. T cells and adaptive immunity to Mycobacterium tuberculosis in humans. Immunol Rev. 2015;264(1):74-87.

[61] Dustin ML. T-cell activation through immunological synapses and kinapses. Immunol Rev. 2008;221:77-89.

[62] Musvosvi M, Huang H, Wang C, et al. T cell receptor repertoires associated with control and disease progression following Mycobacterium tuberculosis infection. Nat Med. 2023;29(1):258-269.

[63] Allison JP. CD28-B7 interactions in T-cell activation. Curr Opin Immunol. 1994;6(3):414-419.

[64] Sekiya T, Yoshimura A. In vitro th differentiation protocol. Methods Mol Biol. 2016;1344:183-191.

[65] Geginat J, Paroni M, Maglie S, et al. Plasticity of human CD4 T cell subsets. Front Immunol. 2014;5:630.

[66] Cowley SC, Elkins KL. CD4+ T cells mediate IFN-gamma-independent control of Mycobacterium tuberculosis infection both in vitro and in vivo. J Immunol. 2003;171(9):4689-4699.

[67] Yahagi A, Umemura M, Tamura T, et al. Suppressed induction of mycobacterial antigen-specific Th1-type CD4+ T cells in the lung after pulmonary mycobacterial infection. Int Immunol. 2010;22(4):307-318.

[68] Ouyang W, Kolls JK, Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity. 2008;28(4):454-467.

[69] Knochelmann HM, Dwyer CJ, Bailey SR, et al. When worlds collide: Th17 and Treg cells in cancer and autoimmunity. Cell Mol Immunol. 2018;15(5):458-469.

[70] Jenkins MR, Griffiths GM. The synapse and cytolytic machinery of cytotoxic T cells. Curr Opin Immunol. 2010;22(3):308-313.

[71] Lord SJ, Rajotte RV, Korbutt GS, Bleackley RC. Granzyme B: A natural born killer. Immunol Rev. 2003;193:31-38.

[72] Ashkenazi A, Dixit VM. Death receptors: Signaling and modulation. Science. 1998;281(5381):1305-1308.

[73] Nathan CF, Murray HW, Wiebe ME, Rubin BY. Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med. 1983;158(3):670-689.

[74] Aqbi HF, Wallace M, Sappal S, Payne KK, Manjili MH. IFN-γ orchestrates tumor elimination, tumor dormancy, tumor escape, and progression. J Leukoc Biol. 2018.

[75] Seder RA, Hill AV. Vaccines against intracellular infections requiring cellular immunity. Nature. 2000;406(6797):793-798.

[76] Rijnink WF, Ottenhoff THM, Joosten SA. B-cells and antibodies as contributors to effector immune responses in tuberculosis. Front Immunol. 2021;12:640168.

[77] Lund FE, Randall TD. Effector and regulatory B cells: Modulators of CD4+ T cell immunity. Nat Rev Immunol. 2010;10(4):236-247.

[78] Hong S, Zhang Z, Liu H, et al. B cells are the dominant antigen-presenting cells that activate naive CD4(+) T cells upon immunization with a virus-derived nanoparticle antigen. Immunity. 2018;49(4):695-708.e4.

[79] Hua Z, Hou B. The role of B cell antigen presentation in the initiation of CD4+ T cell response. Immunol Rev. 2020;296(1):24-35.

[80] Mosmann T. Complexity or coherence? Cytokine secretion by B cells. Nat Immunol. 2000;1(6):465-466.

[81] Harris DP, Haynes L, Sayles PC, et al. Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat Immunol. 2000;1(6):475-482.

[82] Typiak M, Trzonkowski P, Skotarczak M, Dubaniewicz A. Comparative analysis of fcγ and complement receptors presence on monocytes in pulmonary sarcoidosis and tuberculosis. Int J Mol Sci. 2023;24(11):9713.

[83] Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol. 2008;8(1):34-47.

[84] Nimmerjahn F, Ravetch JV. Fcgamma receptors: Old friends and new family members. Immunity. 2006;24(1):19-28.

[85] Kalergis AM, Ravetch JV. Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells. J Exp Med. 2002;195(12):1653-1659.

[86] Zhai W, Wu F, Zhang Y, Fu Y, Liu Z. The immune escape mechanisms of Mycobacterium tuberculosis. Int J Mol Sci. 2019;20(2):340.

[87] Goldberg MF, Saini NK, Porcelli SA. Evasion of innate and adaptive immunity by Mycobacterium tuberculosis. Microbiol Spectr. 2014;2(5):1-24.

[88] Briken V, Miller JL. Living on the edge: Inhibition of host cell apoptosis by Mycobacterium tuberculosis. Future Microbiol. 2008;3(4):415-422.

[89] Danelishvili L, Yamazaki Y, Selker J, Bermudez LE. Secreted Mycobacterium tuberculosis Rv3654c and Rv3655c proteins participate in the suppression of macrophage apoptosis. PLoS One. 2010;5(5):e10474.

[90] Riendeau CJ, Kornfeld H. THP-1 cell apoptosis in response to Mycobacterial infection. Infect Immun. 2003;71(1):254-259.

[91] Zhang L, Zhang H, Zhao Y, et al. Effects of Mycobacterium tuberculosis ESAT-6/CFP-10 fusion protein on the autophagy function of mouse macrophages. DNA Cell Biol. 2012;31(2):171-179.

[92] Rohde K, Yates RM, Purdy GE, Russell DG. Mycobacterium tuberculosis and the environment within the phagosome. Immunol Rev. 2007;219:37-54.

[93] Schüller S, Neefjes J, Ottenhoff T, Thole J, Young D. Coronin is involved in uptake of Mycobacterium bovis BCG in human macrophages but not in phagosome maintenance. Cell Microbiol. 2001;3(12):785-793.

[94] Loeuillet C, Martinon F, Perez C, Munoz M, Thome M, Meylan PR. Mycobacterium tuberculosis subverts innate immunity to evade specific effectors. J Immunol. 2006;177(9):6245-6255.

[95] Gutierrez MG, Mishra BB, Jordao L, Elliott E, Anes E, Griffiths G. NF-kappa B activation controls phagolysosome fusion-mediated killing of mycobacteria by macrophages. J Immunol. 2008;181(4):2651-2663.

[96] Deretic V, Singh S, Master S, et al. Mycobacterium tuberculosis inhibition of phagolysosome biogenesis and autophagy as a host defence mechanism. Cell Microbiol. 2006;8(5):719-727.

[97] Vergne I, Chua J, Deretic V. Mycobacterium tuberculosis phagosome maturation arrest: Selective targeting of PI3P-dependent membrane trafficking. Traffic. 2003;4(9):600-606.

[98] Dutta RK, Kathania M, Raje M, Majumdar S. IL-6 inhibits IFN-γ induced autophagy in Mycobacterium tuberculosis H37Rv infected macrophages. Int J Biochem Cell Biol. 2012;44(6):942-954.

[99] Padhi A, Pattnaik K, Biswas M, Jagadeb M, Behera A, Sonawane A. Mycobacterium tuberculosis LprE suppresses TLR2-dependent cathelicidin and autophagy expression to enhance bacterial survival in macrophages. J Immunol. 2019;203(10):2665-2678.

[100] Rekha RS, Rao Muvva SS, Wan M, et al. Phenylbutyrate induces LL-37-dependent autophagy and intracellular killing of Mycobacterium tuberculosis in human macrophages. Autophagy. 2015;11(9):1688-1699.

[101] Ishikawa E, Mori D, Yamasaki S. Recognition of Mycobacterial lipids by immune receptors. Trends Immunol. 2017;38(1):66-76.

[102] Sinha A, Singh A, Satchidanandam V, Natarajan K. Impaired generation of reactive oxygen species during differentiation of dendritic cells (DCs) by Mycobacterium tuberculosis secretory antigen (MTSA) and subsequent activation of MTSA-DCs by mycobacteria results in increased intracellular survival. J Immunol. 2006;177(1):468-478.

[103] Su H, Peng B, Zhang Z, Liu Z, Zhang Z. The Mycobacterium tuberculosis glycoprotein Rv1016c protein inhibits dendritic cell maturation, and impairs Th1 /Th17 responses during mycobacteria infection. Mol Immunol. 2019;109:58-70.

[104] Chen X, Zhou B, Li M, et al. CD4(+)CD25(+)FoxP3(+) regulatory T cells suppress Mycobacterium tuberculosis immunity in patients with active disease. Clin Immunol. 2007;123(1):50-59.

[105] Li L, Lao SH, Wu CY. Increased frequency of CD4(+)CD25(high) Treg cells inhibit BCG-specific induction of IFN-gamma by CD4(+) T cells from TB patients. Tuberculosis (Edinb). 2007;87(6):526-534.

[106] Marin ND, París SC, Vélez VM, Rojas CA, Rojas M, García LF. Regulatory T cell frequency and modulation of IFN-gamma and IL-17 in active and latent tuberculosis. Tuberculosis (Edinb). 2010;90(4):252-261.

[107] Chandra P, Grigsby SJ, Philips JA. Immune evasion and provocation by Mycobacterium tuberculosis. Nat Rev Microbiol. 2022;20(12):750-766.

[108] Urdahl KB. Understanding and overcoming the barriers to T cell-mediated immunity against tuberculosis. Semin Immunol. 2014;26(6):578-587.

[109] WHO. Global Tuberculosis Report 2022. Vol. 2022. World Health Organization; 2022:1-49. Accessed Oct 30, 2022. https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022

[110] Yong YK, Tan HY, Saeidi A, et al. Immune biomarkers for diagnosis and treatment monitoring of tuberculosis: Current developments and future prospects. Front Microbiol. 2019;10:2789.

[111] Kell DB, Oliver SG. Here is the evidence, now what is the hypothesis? The complementary roles of inductive and hypothesis-driven science in the post-genomic era. Bioessays. 2004;26(1):99-105.

[112] Ahamad N, Gupta S, Parashar D. Using omics to study leprosy, tuberculosis, and other mycobacterial diseases. Front Cell Infect Microbiol. 2022;12:792617.

[113] Hur YG, Kim A, Kang YA, et al. Evaluation of antigen-specific immunoglobulin g responses in pulmonary tuberculosis patients and contacts. J Clin Microbiol. 2015;53(3):904-909.

[114] Cao SH, Chen YQ, Sun Y, et al. Screening of serum biomarkers for distinguishing between latent and active tuberculosis using proteome microarray. Biomed Environ Sci. 2018;31(7):515-526.

[115] Li J, Wang Y, Yan L, et al. Novel serological biomarker panel using protein microarray can distinguish active TB from latent TB infection. Microbes Infect. 2022;24(8):105002.

[116] Maekura R, Kitada S, Osada-Oka M, et al. Serum antibody profiles in individuals with latent Mycobacterium tuberculosis infection. Microbiol Immunol. 2019;63(3-4):130-138.

[117] Cole ST, Brosch R, Parkhill J, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature. 1998;393(6685):537-544.

[118] Chang SY, Chen ML, Lee MR, et al. SP110 polymorphisms are genetic markers for vulnerability to latent and active tuberculosis infection in Taiwan. Dis Markers. 2018;2018:4687380.

[119] Wang S, He L, Wu J, et al. Transcriptional profiling of human peripheral blood mononuclear cells identifies diagnostic biomarkers that distinguish active and latent tuberculosis. Front Immunol. 2019;10:2948.

[120] Huang ZK, Yao FY, Xu JQ, et al. Microarray expression profile of circular RNAs in peripheral blood mononuclear cells from active tuberculosis patients. Cell Physiol Biochem. 2018;45(3):1230-1240.

[121] Angria N, Massi MN, Bukhari A, et al. Expression of miRNA-29a-3p and IFN-γ as biomarkers in active and latent pulmonary tuberculosis. Ann Med Surg (Lond). 2022;83:104786.

[122] Wu H, Yang L, Chen LL. The diversity of long noncoding RNAs and their generation. Trends Genet. 2017;33(8):540-552.

[123] Hu X, Liao S, Bai H, et al. Long noncoding RNA and predictive model to improve diagnosis of clinically diagnosed pulmonary tuberculosis. J Clin Microbiol. 2020;58(7):e01973.

[124] Skalsky RL, Cullen BR. Viruses, microRNAs, and host interactions. Annu Rev Microbiol. 2010;64:123-141.

[125] Kristensen LS, Andersen MS, Stagsted LVW, Ebbesen KK, Hansen TB, Kjems J. The biogenesis, biology and characterization of circular RNAs. Nat Rev Genet. 2019;20(11):675-691.

[126] Ojha R, Nandani R, Chatterjee N, Prajapati VK. Emerging role of circular RNAs as potential biomarkers for the diagnosis of human diseases. Adv Exp Med Biol. 2018;1087:141-157.

[127] Luo J, Zhang M, Yan B, et al. Diagnostic performance of plasma cytokine biosignature combination and MCP-1 as individual biomarkers for differentiating stages Mycobacterium tuberculosis infection. J Infect. 2019;78(4):281-291.

[128] Ferrara G, Losi M, Fabbri LM, Migliori GB, Richeldi L, Casali L. Exploring the immune response against Mycobacterium tuberculosis for a better diagnosis of the infection. Arch Immunol Ther Exp (Warsz). 2009;57(6):425-433.

[129] Mori T, Sakatani M, Yamagishi F, et al. Specific detection of tuberculosis infection: An interferon-gamma-based assay using new antigens. Am J Respir Crit Care Med. 2004;170(1):59-64.

[130] Lalvani A, Nagvenkar P, Udwadia Z, et al. Enumeration of T cells specific for RD1-encoded antigens suggests a high prevalence of latent Mycobacterium tuberculosis infection in healthy urban Indians. J Infect Dis. 2001;183(3):469-477.

[131] Delemarre EM, van Hoorn L, Bossink AWJ, et al. Serum biomarker profile including CCL1, CXCL10, VEGF, and adenosine deaminase activity distinguishes active from remotely acquired latent tuberculosis. Front Immunol. 2021;12:725447.

[132] Qiu X, Xiong T, Su X, et al. Accumulate evidence for IP-10 in diagnosing pulmonary tuberculosis. BMC Infect Dis. 2019;19(1):924.

[133] Rajendran P, Padmapriyadarsini C, Nair S, Sivakumar S. Newer TB diagnostics: An update. Indian J Tuberc. 2023;70(3):372-375.

[134] Wang Y, He Y, Wang L, Zhang Y-A, Wang M-S. Diagnostic yield of nucleic acid amplification tests in oral samples for pulmonary tuberculosis: A systematic review and meta-analysis. Open Forum Infect Dis. 2023;10(3):ofad082.

[135] Gilani B, Sergent SR. Interferon test. StatPearls. StatPearls Publishing; 2023.

[136] Leboueny M, Maloupazoa Siawaya AC, Bouanga LDJ, Mvoundza Ndjindji O, Mveang Nzoghe A, Djoba Siawaya JF. Changes of C-reactive protein and Procalcitonin after four weeks of treatment in patients with pulmonary TB. J Clin Tuberc Other Mycobact Dis. 2023;31:100348.

[137] Mohamed MA, Ali OA, Osman AM, et al. Assessment of drug-susceptible and multidrug-resistant tuberculosis (MDR-TB) in the Central Region of Somalia: A 3-year retrospective study. PLoS Glob Public Health. 2023;3(9):e0002319.

[138] Deng Y, Ma Z, Su B, et al. Accuracy of the InnowaveDX MTB/RIF test for detection of Mycobacterium tuberculosis and rifampicin resistance: A prospective multicentre study. Emerg Microbes Infect. 2023;12(1):2151382.

[139] Hashemian SM, Shafigh N, Afzal G, et al. Plasmapheresis reduces cytokine and immune cell levels in COVID-19 patients with acute respiratory distress syndrome (ARDS). Pulmonology. 2021;27(6):486-492.

[140] Dalil Roofchayee N, Marjani M, Dezfuli NK, et al. Potential diagnostic value of pleural fluid cytokines levels for tuberculous pleural effusion. Sci Rep. 2021;11(1):660.

[141] Zheng X, Gui X, Yao L, et al. Efficacy and safety of an innovative short-course regimen containing clofazimine for treatment of drug-susceptible tuberculosis: A clinical trial. Emerg Microbes Infect. 2023;12(1):2187247.

[142] Sileshi T, Telele NF, Burkley V, Makonnen E, Aklillu E. Correlation of N-acetyltransferase 2 genotype and acetylation status with plasma isoniazid concentration and its metabolic ratio in ethiopian tuberculosis patients. Sci Rep. 2023;13(1):11438.

[143] du Toit LC, Pillay V, Danckwerts MP. Tuberculosis chemotherapy: Current drug delivery approaches. Respir Res. 2006;7(1):118.

[144] Glaziou P, Floyd K, Raviglione MC. Global epidemiology of tuberculosis. Semin Respir Crit Care Med. 2018;39(3):271-285.

[145] Mi J, Liang Y, Liang J, et al. The research progress in immunotherapy of tuberculosis. Front Cell Infect Microbiol. 2021;11:763591.

[146] Gonzalez-Juarrero M. Immunity to TB and targets for immunotherapy. Immunotherapy. 2012;4(2):187-199.

[147] Brett K, Dulong C, Severn M. CADTH rapid response Reports. Treatment of Tuberculosis: A Review of Guidelines. Canadian Agency for Drugs and Technologies in Health; 2020.

[148] WHO. WHO guidelines approved by the guidelines review committee. Guidelines on the Management of Latent Tuberculosis Infection. World Health Organization; 2015.

[149] Houben RM, Dodd PJ. The global burden of latent tuberculosis infection: A re-estimation using mathematical modelling. PLoS Med. 2016;13(10):e1002152.

[150] Jiang F, Peng C, Cheng P, Wang J, Lian J, Gong W. PP19128R, a multiepitope vaccine designed to prevent latent tuberculosis infection, induced immune responses in silico and in vitro assays. Vaccines (Basel). 2023;11(4):856.

[151] Du J, Su Y, Dong E, et al. LTBI-negative close contacts of tuberculosis are more likely to develop the disease: Enlightenment and lessons from a cluster outbreak. Front Public Health. 2023;11(2023):1136355.

[152] Sterling TR, Njie G, Zenner D, Cohn DL, Belknap R. Guidelines for the treatment of latent tuberculosis infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020. Am J Transplant. 2020;20(4):1196-1206.

[153] WHO. WHO guidelines approved by the guidelines review committee. WHO Consolidated Guidelines on Tuberculosis: Module 4: Treatment - Drug-Susceptible Tuberculosis Treatment. World Health Organization; 2022.

[154] Dookie N, Ngema SL, Perumal R, Naicker N, Padayatchi N, Naidoo K. The changing paradigm of drug-resistant tuberculosis treatment: Successes, pitfalls, and future perspectives. Clin Microbiol Rev. 2022;35(4):e0018019.

[155] WHO. WHO guidelines approved by the guidelines review committee. WHO Consolidated Guidelines on Tuberculosis: Module 4: Treatment - Drug-Resistant Tuberculosis Treatment. World Health Organization; 2020.

[156] Koul A, Dendouga N, Vergauwen K, et al. Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat Chem Biol. 2007;3(6):323-324.

[157] Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med. 2009;360(23):2397-2405.

[158] Lv X, Tang S, Xia Y, et al. Adverse reactions due to directly observed treatment strategy therapy in Chinese tuberculosis patients: A prospective study. PLoS One. 2013;8(6):e65037.

[159] Munro SA, Lewin SA, Smith HJ, Engel ME, Fretheim A, Volmink J. Patient adherence to tuberculosis treatment: A systematic review of qualitative research. PLoS Med. 2007;4(7):e238.

[160] Horsburgh CR,, Barry CE,, Lange C. Treatment of tuberculosis. N Engl J Med. 2015;373(22):2149-2160.

[161] Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science. 2005;307(5707):223-227.

[162] Worley MV, Estrada SJ. Bedaquiline: A novel antitubercular agent for the treatment of multidrug-resistant tuberculosis. Pharmacotherapy. 2014;34(11):1187-1197.

[163] Matsumoto M, Hashizume H, Tomishige T, et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med. 2006;3(11):e466.

[164] Lewis JM, Sloan DJ. The role of delamanid in the treatment of drug-resistant tuberculosis. Ther Clin Risk Manag. 2015;11:779-791.

[165] Saliu OY, Crismale C, Schwander SK, Wallis RS. Bactericidal activity of OPC-67683 against drug-tolerant Mycobacterium tuberculosis. J Antimicrob Chemother. 2007;60(5):994-998.

[166] Sasaki H, Haraguchi Y, Itotani M, et al. Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles. J Med Chem. 2006;49(26):7854-7860.

[167] Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med. 2012;366(23):2151–2160.

[168] Wishart DS, Knox C, Guo AC, et al. DrugBank: A comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 2006;34(Database issue):D668-D672.

[169] Stover CK, Warrener P, VanDevanter DR, et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature. 2000;405(6789):962-966.

[170] Rivers EC, Mancera RL. New anti-tuberculosis drugs in clinical trials with novel mechanisms of action. Drug Discov Today. 2008;13(23-24):1090-1098.

[171] AlMatar M, AlMandeal H, Var I, Kayar B, Köksal F. New drugs for the treatment of Mycobacterium tuberculosis infection. Biomed Pharmacother. 2017;91:546-558.

[172] Chetty S, Ramesh M, Singh-Pillay A, Soliman ME. Recent advancements in the development of anti-tuberculosis drugs. Bioorg Med Chem Lett. 2017;27(3):370-386.

[173] Nuermberger E, Tyagi S, Tasneen R, et al. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrob Agents Chemother. 2008;52(4):1522-1524.

[174] Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: A randomised trial. Lancet. 2012;380(9846):986-993.

[175] Dawson R, Diacon AH, Everitt D, et al. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: A phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Lancet. 2015;385(9979):1738-1747.

[176] Lessem E. The tuberculosis treatment pipeline: Activity, but no answers. Treatment Action Group. October 13, 2023. Accessed October 13, 2023. https://www.treatmentactiongroup.org/resources/pipeline-report/2016-pipeline-report/the-tuberculosis-treatment-pipeline-activity-but-no-answers/#:~:text=New%20guidelines%20from%20the%20World%20Health%20Organization%20%28WHO%29,yet%20to%20be%20validated%20in%20randomized%20controlled%20trials

[177] Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline. Am J Respir Crit Care Med. 2015;191(8):943-953.

[178] Jiao X, Lo-Man R, Guermonprez P, et al. Dendritic cells are host cells for mycobacteria in vivo that trigger innate and acquired immunity. J Immunol. 2002;168(3):1294-1301.

[179] Flesch I, Kaufmann SH. Mycobacterial growth inhibition by interferon-gamma-activated bone marrow macrophages and differential susceptibility among strains of Mycobacterium tuberculosis. J Immunol. 1987;138(12):4408-4413.

[180] Tan Q, Min R, Dai GQ, et al. Clinical and immunological effects of rhIL-2 therapy in Eastern Chinese patients with multidrug-resistant tuberculosis. Sci Rep. 2017;7(1):17854.

[181] Pedral-Sampaio DB, Netto EM, Brites C, et al. Use of Rhu-GM-CSF in pulmonary tuberculosis patients: Results of a randomized clinical trial. Braz J Infect Dis. 2003;7(4):245-252.

[182] Gong W, Mi J, Wu X. [Immunologically active substances: Novel treatment options for tuberculosis and nontuberculous Mycobacteriosis]. Chin J Antituberc. 2022;44(11):1107-1121.

[183] Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med. 1993;178(6):2249-2254.

[184] Flynn JL, Goldstein MM, Chan J, et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity. 1995;2(6):561-572.

[185] Denis M, Ghadirian E. Immunotherapy of airborne tuberculosis in mice via the lung-specific delivery of cytokines. Can J Infect Dis. 1993;4(1):38-42.

[186] Appelberg R, Castro AG, Pedrosa J, Silva RA, Orme IM, Minóprio P. Role of gamma interferon and tumor necrosis factor alpha during T-cell-independent and -dependent phases of Mycobacterium avium infection. Infect Immun. 1994;62(9):3962-3971.

[187] Reljic R. IFN-gamma therapy of tuberculosis and related infections. J Interferon Cytokine Res. 2007;27(5):353-364.

[188] Condos R, Rom WN, Schluger NW. Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol. Lancet. 1997;349(9064):1513-1515.

[189] Giosué S, Casarini M, Alemanno L, et al. Effects of aerosolized interferon-alpha in patients with pulmonary tuberculosis. Am J Respir Crit Care Med. 1998;158(4):1156-1162.

[190] Jeevan A, Asherson GL. Recombinant interleukin-2 limits the replication of Mycobacterium lepraemurium and Mycobacterium bovis BCG in mice. Infect Immun. 1988;56(3):660-664.

[191] Bermudez LE, Stevens P, Kolonoski P, Wu M, Young LS. Treatment of experimental disseminated Mycobacterium avium complex infection in mice with recombinant IL-2 and tumor necrosis factor. J Immunol. 1989;143(9):2996-3000.

[192] Johnson BJ, Ress SR, Willcox P, et al. Clinical and immune responses of tuberculosis patients treated with low-dose IL-2 and multidrug therapy. Cytokines Mol Ther. 1995;1(3):185-196.

[193] Johnson B, Bekker LG, Ress S, Kaplan G. Recombinant interleukin 2 adjunctive therapy in multidrug-resistant tuberculosis. Novartis Found Symp. 1998;217:99-106; discussion 106–11.

[194] Johnson JL, Ssekasanvu E, Okwera A, et al. Randomized trial of adjunctive interleukin-2 in adults with pulmonary tuberculosis. Am J Respir Crit Care Med. 2003;168(2):185-191.

[195] Zhang R, Xi X, Wang C, et al. Therapeutic effects of recombinant human interleukin 2 as adjunctive immunotherapy against tuberculosis: A systematic review and meta-analysis. PLoS One. 2018;13(7):e0201025.

[196] Zhang Y, Liu J, Wang Y, et al. Immunotherapy using IL-2 and GM-CSF is a potential treatment for multidrug-resistant Mycobacterium tuberculosis. Sci China Life Sci. 2012;55(9):800-806.

[197] Francisco-Cruz A, Mata-Espinosa D, Ramos-Espinosa O, et al. Efficacy of gene-therapy based on adenovirus encoding granulocyte-macrophage colony-stimulating factor in drug-sensitive and drug-resistant experimental pulmonary tuberculosis. Tuberculosis (Edinb). 2016;100:5-14.

[198] Li B, Chan HL, Chen P. Immune checkpoint inhibitors: Basics and challenges. Curr Med Chem. 2019;26(17):3009-3025.

[199] Wykes MN, Lewin SR. Immune checkpoint blockade in infectious diseases. Nat Rev Immunol. 2018;18(2):91-104.

[200] Jiang X, Wang J, Deng X, et al. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol Cancer. 2019;18(1):10.

[201] Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7):1027-1034.

[202] Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677-704.

[203] Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol. 2004;173(2):945-954.

[204] Kamboj D, Gupta P, Basil MV, et al. Improved Mycobacterium tuberculosis clearance after the restoration of IFN-γ(+) TNF-α(+) CD4(+) T cells: Impact of PD-1 inhibition in active tuberculosis patients. Eur J Immunol. 2020;50(5):736-747.

[205] Suarez GV, Melucci Ganzarain CDC, Vecchione MB, et al. PD-1/PD-L1 pathway modulates macrophage susceptibility to Mycobacterium tuberculosis specific CD8(+) T cell induced death. Sci Rep. 2019;9(1):187.

[206] Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature. 1992;356(6370):607-609.

[207] Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med. 1995;182(2):459-465.

[208] Maçon-Lemaître L, Triebel F. The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells. Immunology. 2005;115(2):170-178.

[209] Poirier N, Haudebourg T, Brignone C, et al. Antibody-mediated depletion of lymphocyte-activation gene-3 (LAG-3(+))-activated T lymphocytes prevents delayed-type hypersensitivity in non-human primates. Clin Exp Immunol. 2011;164(2):265-274.

[210] Workman CJ, Wang Y, El Kasmi KC, et al. LAG-3 regulates plasmacytoid dendritic cell homeostasis. J Immunol. 2009;182(4):1885-1891.

[211] Andreae S, Piras F, Burdin N, Triebel F. Maturation and activation of dendritic cells induced by lymphocyte activation gene-3 (CD223). J Immunol. 2002;168(8):3874-3880.

[212] Mehra S, Pahar B, Dutta NK, et al. Transcriptional reprogramming in nonhuman primate (rhesus macaque) tuberculosis granulomas. PLoS One. 2010;5(8):e12266.

[213] Phillips BL, Mehra S, Ahsan MH, Selman M, Khader SA, Kaushal D. LAG3 expression in active Mycobacterium tuberculosis infections. Am J Pathol. 2015;185(3):820-833.

[214] Meyers JH, Sabatos CA, Chakravarti S, Kuchroo VK. The TIM gene family regulates autoimmune and allergic diseases. Trends Mol Med. 2005;11(8):362-369.

[215] Monney L, Sabatos CA, Gaglia JL, et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature. 2002;415(6871):536-541.

[216] Dixon KO, Tabaka M, Schramm MA, et al. TIM-3 restrains anti-tumour immunity by regulating inflammasome activation. Nature. 2021;595(7865):101-106.

[217] Tang R, Acharya N, Subramanian A, et al. Tim-3 adapter protein Bat3 acts as an endogenous regulator of tolerogenic dendritic cell function. Sci Immunol. 2022;7(69):eabm0631.

[218] Jayaraman P, Jacques MK, Zhu C, et al. TIM3 mediates T cell exhaustion during Mycobacterium tuberculosis infection. PLoS Pathog. 2016;12(3):e1005490.

[219] Langan EA, Graetz V, Allerheiligen J, Zillikens D, Rupp J, Terheyden P. Immune checkpoint inhibitors and tuberculosis: An old disease in a new context. Lancet Oncol. 2020;21(1):e55-e65.

[220] van Eeden R, Rapoport BL, Smit T, Anderson R. Tuberculosis infection in a patient treated with nivolumab for non-small cell lung cancer: Case report and literature review. Front Oncol. 2019;9:659.

[221] Lee JJ, Chan A, Tang T. Tuberculosis reactivation in a patient receiving anti-programmed death-1 (PD-1) inhibitor for relapsed Hodgkin's lymphoma. Acta Oncol. 2016;55(4):519-520.

[222] Efremenko YV, Butov DA, Prihoda ND, et al. Randomized, placebo-controlled phase II trial of heat-killed Mycobacterium vaccae (Longcom batch) formulated as an oral pill (V7). Hum Vaccin Immunother. 2013;9(9):1852-1856.

[223] Sharma SK, Katoch K, Sarin R, et al. Efficacy and Safety of Mycobacterium indicus pranii as an adjunct therapy in Category II pulmonary tuberculosis in a randomized trial. Sci Rep. 2017;7(1):3354.

[224] Mayosi BM, Ntsekhe M, Bosch J, et al. Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis. N Engl J Med. 2014;371(12):1121-1130.

[225] von Reyn CF, Lahey T, Arbeit RD, et al. Safety and immunogenicity of an inactivated whole cell tuberculosis vaccine booster in adults primed with BCG: A randomized, controlled trial of DAR-901. PLoS One. 2017;12(5):e0175215.

[226] Munseri P, Said J, Amour M, et al. DAR-901 vaccine for the prevention of infection with Mycobacterium tuberculosis among BCG-immunized adolescents in Tanzania: A randomized controlled, double-blind phase 2b trial. Vaccine. 2020;38(46):7239-7245.

[227] Vilaplana C, Montané E, Pinto S, et al. Double-blind, randomized, placebo-controlled Phase I Clinical Trial of the therapeutical antituberculous vaccine RUTI. Vaccine. 2010;28(4):1106-1116.

[228] Nell AS, D'Lom E, Bouic P, et al. Safety, tolerability, and immunogenicity of the novel antituberculous vaccine RUTI: Randomized, placebo-controlled phase II clinical trial in patients with latent tuberculosis infection. PLoS One. 2014;9(2):e89612.

[229] Von Eschen K, Morrison R, Braun M, et al. The candidate tuberculosis vaccine Mtb72F/AS02A: Tolerability and immunogenicity in humans. Hum Vaccin. 2009;5(7):475-482.

[230] Leroux-Roels I, Forgus S, De Boever F, et al. Improved CD4⁺ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: A randomized trial. Vaccine. 2013;31(17):2196-2206.

[231] Tait DR, Hatherill M, Van Der Meeren O, et al. Final analysis of a trial of M72/AS01(E) vaccine to prevent tuberculosis. N Engl J Med. 2019;381(25):2429-2439.

[232] Luabeya AK, Kagina BM, Tameris MD, et al. First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults. Vaccine. 2015;33(33):4130-4140.

[233] Bekker LG, Dintwe O, Fiore-Gartland A, et al. A phase 1b randomized study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in Mycobacterium tuberculosis-uninfected adolescents in Cape Town, South Africa. EClinicalMedicine. 2020;21:100313.

[234] Jenum S, Tonby K, Rueegg CS, et al. A Phase I/II randomized trial of H56:IC31 vaccination and adjunctive cyclooxygenase-2-inhibitor treatment in tuberculosis patients. Nat Commun. 2021;12(1):6774.

[235] Suliman S, Luabeya AKK, Geldenhuys H, et al. Dose optimization of H56:IC31 vaccine for tuberculosis-endemic populations. a double-blind, placebo-controlled, dose-selection trial. Am J Respir Crit Care Med. 2019;199(2):220-231.

[236] Day TA, Penn-Nicholson A, Luabeya AKK, et al. Safety and immunogenicity of the adjunct therapeutic vaccine ID93+GLA-SE in adults who have completed treatment for tuberculosis: A randomised, double-blind, placebo-controlled, phase 2a trial. Lancet Respir Med. 2021;9(4):373-386.

[237] Gong WP, Liang Y, Ling YB, et al. Effects of Mycobacterium vaccae vaccine in a mouse model of tuberculosis: Protective action and differentially expressed genes. Mil Med Res. 2020;7(1):25.

[238] Stanford JL, Stanford CA. Immunotherapy with Mycobacterium vaccae and the treatment of tuberculosis. Soc Appl Bacteriol Symp Ser. 1996;25:81s-86s.

[239] Rodríguez-Güell E, Agustí G, Corominas M, Cardona PJ, Luquin M, Julián E. Mice with pulmonary tuberculosis treated with Mycobacterium vaccae develop strikingly enhanced recall gamma interferon responses to M. vaccae cell wall skeleton. Clin Vaccine Immunol. 2008;15(5):893-896.

[240] Huang CY, Hsieh WY. Efficacy of Mycobacterium vaccae immunotherapy for patients with tuberculosis: A systematic review and meta-analysis. Hum Vaccin Immunother. 2017;13(9):1960-1971.

[241] Gong W, Liang Y, Wu X. The current status, challenges, and future developments of new tuberculosis vaccines. Hum Vacc Immunother. 2018;14(7):1697-1716.

[242] Weng H, Huang JY, Meng XY, Li S, Zhang GQ. Adjunctive therapy of Mycobacterium vaccae vaccine in the treatment of multidrug-resistant tuberculosis: A systematic review and meta-analysis. Biomed Rep. 2016;4(5):595-600.

[243] Yang XY, Chen QF, Li YP, Wu SM. Mycobacterium vaccae as adjuvant therapy to anti-tuberculosis chemotherapy in never-treated tuberculosis patients: A meta-analysis. PLoS One. 2011;6(9):e23826.

[244] de B, Garner P. Mycobacterium vaccae immunotherapy for treating tuberculosis. Cochrane Database Syst Rev. 2001;(1):Cd001166.

[245] Das S, Chowdhury BP, Goswami A, et al. Mycobacterium indicus pranii (MIP) mediated host protective intracellular mechanisms against tuberculosis infection: Involvement of TLR-4 mediated signaling. Tuberculosis (Edinb). 2016;101:201-209.

[246] Saini V, Raghuvanshi S, Talwar GP, et al. Polyphasic taxonomic analysis establishes Mycobacterium indicus pranii as a distinct species. PLoS One. 2009;4(7):e6263.

[247] Gupta A, Ahmad FJ, Ahmad F, et al. Efficacy of Mycobacterium indicus pranii immunotherapy as an adjunct to chemotherapy for tuberculosis and underlying immune responses in the lung. PLoS One. 2012;7(7):e39215.

[248] Patel N, Deshpande MM, Shah M. Effect of an immunomodulator containing Mycobacterium w on sputum conversion in pulmonary tuberculosis. J Indian Med Assoc. 2002;100(3):191-193.

[249] Patel N, Trapathi SB. Improved cure rates in pulmonary tuberculosis category II (retreatment) with mycobacterium w. J Indian Med Assoc. 2003;101(11):680-682.

[250] Guirado E, Gil O, Cáceres N, Singh M, Vilaplana C, Cardona PJ. Induction of a specific strong polyantigenic cellular immune response after short-term chemotherapy controls bacillary reactivation in murine and guinea pig experimental models of tuberculosis. Clin Vaccine Immunol. 2008;15(8):1229-1237.

[251] Cardona PJ, Amat I. Origin and development of RUTI, a new therapeutic vaccine against Mycobacterium tuberculosis infection. Arch Bronconeumol. 2006;42(1):25-32.

[252] Cardona PJ. The progress of therapeutic vaccination with regard to tuberculosis. Front Microbiol. 2016;7:1536.

[253] Cardona PJ. RUTI: A new chance to shorten the treatment of latent tuberculosis infection. Tuberculosis (Edinb). 2006;86(3-4):273-289.

[254] Cardona PJ, Amat I, Gordillo S, et al. Immunotherapy with fragmented Mycobacterium tuberculosis cells increases the effectiveness of chemotherapy against a chronical infection in a murine model of tuberculosis. Vaccine. 2005;23(11):1393-1398.

[255] Van Der Meeren O, Hatherill M, Nduba V, et al. Phase 2b controlled trial of M72/AS01(E) vaccine to prevent tuberculosis. N Engl J Med. 2018;379(17):1621-1634.

[256] Aagaard C, Hoang T, Dietrich J, et al. A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat Med. 2011;17(2):189-194.

[257] Baldwin SL, Reese VA, Huang PW, et al. Protection and long-lived immunity induced by the ID93/GLA-SE vaccine candidate against a clinical Mycobacterium tuberculosis isolate. Clin Vaccine Immunol. 2016;23(2):137-147.

[258] Bertholet S, Ireton GC, Ordway DJ, et al. A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis. Sci Transl Med. 2010;2(53):53ra74.

[259] Baldwin SL, Reese VA, Larsen SE, et al. Prophylactic efficacy against Mycobacterium tuberculosis using ID93 and lipid-based adjuvant formulations in the mouse model. PLoS One. 2021;16(3):e0247990.

[260] Gomez M, McCollum J, Wang H, et al. Development of a formulation platform for a spray-dried, inhalable tuberculosis vaccine candidate. Int J Pharm. 2021;593:120121.

[261] Lu JB, Chen BW, Wang GZ, et al. Recombinant tuberculosis vaccine AEC/BC02 induces antigen-specific cellular responses in mice and protects guinea pigs in a model of latent infection. J Microbiol Immunol Infect. 2015;48(6):597-603.

[262] Lu J, Guo X, Wang C, et al. Therapeutic effect of subunit vaccine AEC/BC02 on Mycobacterium tuberculosis post-chemotherapy relapse using a latent infection murine model. Vaccines (Basel). 2022;10(5):825.

[263] MacNeil A, Glaziou P, Sismanidis C, Date A, Maloney S, Floyd K. Global epidemiology of tuberculosis and progress toward meeting global targets - Worldwide, 2018. MMWR Morb Mortal Wkly Rep. 2020;69(11):281-285.

[264] Fine PE. Variation in protection by BCG: Implications of and for heterologous immunity. Lancet. 1995;346(8986):1339-1345.

[265] Colditz GA, Brewer TF, Berkey CS, et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA. 1994;271(9):698-702.

[266] Wiker HG, Mustafa T, Målen H, Riise AM. Vaccine approaches to prevent tuberculosis. Scand J Immunol. 2006;64(3):243-250.

[267] Moyle PM, Toth I. Modern subunit vaccines: Development, components, and research opportunities. ChemMedChem. 2013;8(3):360-376.

[268] Clark S, Lanni F, Marinova D, Rayner E, Martin C, Williams A. Revaccination of guinea pigs with the live attenuated Mycobacterium tuberculosis vaccine MTBVAC Improves BCG's protection against tuberculosis. J Infect Dis. 2017;216(5):525-533.

[269] Hu Z, Lu SH, Lowrie DB, Fan XY. Research advances for virus-vectored tuberculosis vaccines and latest findings on tuberculosis vaccine development. Front Immunol. 2022;13:895020.

[270] Weng S, Zhang J, Ma H, et al. B21 DNA vaccine expressing ag85b, rv2029c, and rv1738 confers a robust therapeutic effect against latent Mycobacterium tuberculosis infection. Front Immunol. 2022;13:1025931.

[271] Halliday A, Jain P, Hoang L, et al. Efficacy and Mechanism Evaluation. New Technologies for Diagnosing Active TB: The VANTDET Diagnostic Accuracy Study. NIHR Journals Library; 2021.

[272] Zhou Z, Zhou X, Cheng L, et al. Machine learning algorithms utilizing blood parameters enable early detection of immunethrombotic dysregulation in COVID-19. Clin Transl Med. 2021;11(9):e523.

[273] Viatgé T, Mazières J, Zahi S, Fajadet P, Pétureau F. Anti-PD1 immunotherapy followed by tuberculosis infection or reactivation. Rev Mal Respir. 2020;37(7):595-601.

[274] Bouzeyen R, Javid B. Therapeutic vaccines for tuberculosis: An overview. Front Immunol. 2022;13:878471.

RIGHTS & PERMISSIONS

2024 2024 The Authors. MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.